Pardis Sabeti

Oct 11, 2024 | nature.com | Sreekar Mantena |Brittany A. Petros |Cameron Myhrvold |Pardis Sabeti

AbstractCRISPR guide RNA sequences deriving exactly from natural sequences may not perform optimally in every application. Here we implement and evaluate algorithms for designing maximally fit, artificial CRISPR–Cas13a guides with multiple mismatches to natural sequences that are tailored for diagnostic applications.

Sep 16, 2024 | thehill.com | Arya S. Rao |Al Ozonoff |Pardis Sabeti

Almost five years after the COVID-19 pandemic began, its central question remains subject to heated debate: Did the SARS-CoV-2 virus originate naturally, or was it leaked from a scientific lab participating in gain-of-function research? This controversy has sparked vitriol from all sides, as politicians and scientists battle publicly over the contents of data from the Wuhan market and the role of NIH-funded research.

Mar 19, 2024 | nature.com | David Yao |Josh Tycko |Lexi R. Bounds |Benjamin Doughty |Alexander White |Xingjie Ren | +16 more

AbstractThe ENCODE Consortium’s efforts to annotate noncoding cis-regulatory elements (CREs) have advanced our understanding of gene regulatory landscapes. Pooled, noncoding CRISPR screens offer a systematic approach to investigate cis-regulatory mechanisms. The ENCODE4 Functional Characterization Centers conducted 108 screens in human cell lines, comprising >540,000 perturbations across 24.85 megabases of the genome.

Feb 6, 2024 | medrxiv.org | Brittany A. Petros |Carly E. Milliren |Pardis Sabeti |Al Ozonoff

PCS is a co-founder of, shareholder in, and advisor to Sherlock Biosciences, Inc.; a board member of and shareholder in the Danaher Corporation; a co-founder of and shareholder in Delve Bio; and a shareholder in NextGenJane and TruGenomix.